Cargando…
1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis
BACKGROUND: Patients with a penicillin (pcn) allergy are less likely to receive cefazolin (cef) and more likely to receive vancomycin (vanco) or clindamycin (clinda) for procedures. Literature reveals a 51% increased risk of surgical site infection in patients with a reported pcn allergy attributed,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678620/ http://dx.doi.org/10.1093/ofid/ofad500.1299 |
_version_ | 1785150405758418944 |
---|---|
author | Veach, Lisa A Bushman, Amanda Wall, Geoff Hadziric, Adela Olstinke, Kayla Blackmer, Sydney |
author_facet | Veach, Lisa A Bushman, Amanda Wall, Geoff Hadziric, Adela Olstinke, Kayla Blackmer, Sydney |
author_sort | Veach, Lisa A |
collection | PubMed |
description | BACKGROUND: Patients with a penicillin (pcn) allergy are less likely to receive cefazolin (cef) and more likely to receive vancomycin (vanco) or clindamycin (clinda) for procedures. Literature reveals a 51% increased risk of surgical site infection in patients with a reported pcn allergy attributed, in multivariable analysis, to use of second line antimicrobial agents. METHODS: We conducted a retrospective review of intravenous vanco and clinda administration in procedural areas during a 6 -month period in 2022. The aim of our study was to assess the appropriateness of the procedural prophylaxis antibiotic given based on the allergy information available in the medical record. Documented allergy responses were classified as: severe, cutaneous and other. Multiple documented reactions were classified using the most severe reaction type. RESULTS: Seven hundred and eighty-eight patient encounters were reviewed: 434 encounters receiving vanco and 354 encounters receiving clinda. Of the encounters receiving vanco, 237 (55%) had documentation of beta lactam allergy (pcn allergy (212), cef allergy (64), both (39)). Within the pcn allergy group, reaction was cutaneous only in 47% (100). In 79 encounters previous receipt of a cephalosporin was documented in the EHR. Of the encounters receiving clinda, 330 (93%) had documentation of a beta lactam allergy (pcn allergy (277), cef allergy (98), both (45)). Within the pcn allergy group, reaction was cutaneous only in 60% (167). In 109 encounters previous receipt of a cephalosporin was documented in the EHR. (Figures 1 and 2) In both groups nursing placed the majority of the vanco (69%) and clinda (70%) orders. [Figure: see text] [Figure: see text] CONCLUSION: At least 55% (N=267) of pcn allergic patients could have received the optimal agent (cefazolin) for procedural prophylaxis as they had only a cutaneous reaction. EHR review for prior cephalosporin administration in non-cutaneous reaction further increases that number. In recognition of the role of nursing, our health system has developed guidance documents to aid pre-op nursing staff in selecting the appropriate surgical prophylaxis antimicrobial in patients reporting pcn allergy. This document is readily available and shared with key stakeholders. Process improvement opportunities are ongoing. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-10678620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106786202023-11-27 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis Veach, Lisa A Bushman, Amanda Wall, Geoff Hadziric, Adela Olstinke, Kayla Blackmer, Sydney Open Forum Infect Dis Abstract BACKGROUND: Patients with a penicillin (pcn) allergy are less likely to receive cefazolin (cef) and more likely to receive vancomycin (vanco) or clindamycin (clinda) for procedures. Literature reveals a 51% increased risk of surgical site infection in patients with a reported pcn allergy attributed, in multivariable analysis, to use of second line antimicrobial agents. METHODS: We conducted a retrospective review of intravenous vanco and clinda administration in procedural areas during a 6 -month period in 2022. The aim of our study was to assess the appropriateness of the procedural prophylaxis antibiotic given based on the allergy information available in the medical record. Documented allergy responses were classified as: severe, cutaneous and other. Multiple documented reactions were classified using the most severe reaction type. RESULTS: Seven hundred and eighty-eight patient encounters were reviewed: 434 encounters receiving vanco and 354 encounters receiving clinda. Of the encounters receiving vanco, 237 (55%) had documentation of beta lactam allergy (pcn allergy (212), cef allergy (64), both (39)). Within the pcn allergy group, reaction was cutaneous only in 47% (100). In 79 encounters previous receipt of a cephalosporin was documented in the EHR. Of the encounters receiving clinda, 330 (93%) had documentation of a beta lactam allergy (pcn allergy (277), cef allergy (98), both (45)). Within the pcn allergy group, reaction was cutaneous only in 60% (167). In 109 encounters previous receipt of a cephalosporin was documented in the EHR. (Figures 1 and 2) In both groups nursing placed the majority of the vanco (69%) and clinda (70%) orders. [Figure: see text] [Figure: see text] CONCLUSION: At least 55% (N=267) of pcn allergic patients could have received the optimal agent (cefazolin) for procedural prophylaxis as they had only a cutaneous reaction. EHR review for prior cephalosporin administration in non-cutaneous reaction further increases that number. In recognition of the role of nursing, our health system has developed guidance documents to aid pre-op nursing staff in selecting the appropriate surgical prophylaxis antimicrobial in patients reporting pcn allergy. This document is readily available and shared with key stakeholders. Process improvement opportunities are ongoing. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10678620/ http://dx.doi.org/10.1093/ofid/ofad500.1299 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Veach, Lisa A Bushman, Amanda Wall, Geoff Hadziric, Adela Olstinke, Kayla Blackmer, Sydney 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis |
title | 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis |
title_full | 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis |
title_fullStr | 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis |
title_full_unstemmed | 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis |
title_short | 1462. Analysis of Clindamycin and Vancomycin Use and Reported Beta Lactam Allergy in Procedural Antimicrobial Prophylaxis |
title_sort | 1462. analysis of clindamycin and vancomycin use and reported beta lactam allergy in procedural antimicrobial prophylaxis |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678620/ http://dx.doi.org/10.1093/ofid/ofad500.1299 |
work_keys_str_mv | AT veachlisaa 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis AT bushmanamanda 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis AT wallgeoff 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis AT hadziricadela 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis AT olstinkekayla 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis AT blackmersydney 1462analysisofclindamycinandvancomycinuseandreportedbetalactamallergyinproceduralantimicrobialprophylaxis |